Exploring Men’s Willingness to Pay for Prostate Cancer Screening to Avoid Unnecessary Biopsy and Treatment

January/February 2013 Vol 6, No 1 - Prostate Cancer
Rosemary Frei, MSc
Medical Writer
Download PDF

Dutch researchers have peered into the minds and wallets of a group of men aged 55 to 75 years to determine what they are willing to trade for a reduced risk of prostate cancer–related death or to avoid unnecessary procedures and treatment.

Men with more education had a lower probability of opting for prostate cancer screening. Furthermore, in aggregate, the men were willing to lose 2% of risk reduction in mortality related to prostate cancer or to pay on average €188 (in 2010 Euros; equivalent to $245 in 2010 US dollars) annually for a 10% reduced risk of unnecessary biopsy or treatment.

“Physicians should be aware that men, particularly those with less education, may overestimate the benefit of prostate cancer screening, due to numeracy problems...and that therefore tailored prostate cancer screening programs may result in a better-informed shared decision-making for screening,” wrote Esther W. de Bekker-Grob, PhD, a researcher and health economist at Erasmus Medical Center, Rotterdam, the Netherlands, and her colleagues (de Bekker-Grob EW, et al. Br J Cancer. 2013 Jan 29 [Epub ahead of print]).

“Increasing knowledge on overdiagnosis and overtreatment, especially for men with lower educational levels, is warranted to prevent unrealistic expectations from prostate cancer screening,” she continued.

The team formulated 2 versions of a questionnaire containing 16 choice sets on prostate cancer screening. These were based on the prostate cancer screening literature and interviews with 8 prostate cancer experts. A total of 459 men (average age, 63.3 years) from southwest Holland responded to the questionnaires.
The researchers divided the men into 3 groups:

  • Most men in the first group had a lower educational level, did not have anxiety or depression, and were willing to pay for prostate cancer screening
  • Most men in the second group also had a lower educational level and did not have anxiety or depression, but they were not willing to pay for screening
  • The third group largely comprised men who had a higher educational level, had anxiety or depression, and were not willing to pay for prostate cancer screening.

The men in all 3 groups indicated that a reduction in the risk of developing prostate cancer, a reduction in the risk of unnecessary treatment and biopsy, and costs are all important.

Those in the first group had a preference for annual or biennial screening, those in the second group did not have a preference for shorter or for longer screening intervals, and members of the third group preferred screening every 2 years versus screening every 4 years.

Willingness to Pay
When all 3 groups were combined, the men were willing to pay an average cost of:

  • €188 (or $245 US) for a 10% reduction in prostate cancer–related death
  • €33 ($43 US) annually for a 10% reduction in the risk of an unnecessary prostate biopsy
  • €38 ($50 US) annually for a 10% decrease in the risk of undergoing unnecessary treatment
  • €87 ($115 US) annually to access a prostate cancer screening program with a 2-year interval rather than a 4-year interval.

In addition, the men were willing to exchange 2% of the reduced risk of prostate cancer mortality for a 10% reduction in unnecessary treatment.
The men were also willing to trade 1.8% of their reduced mortality risk for a 10% reduction in the probability of an unnecessary biopsy, and a 4.6% reduced risk of prostate cancer–related death for a 2-year screening interval rather than a 4-year screening interval.

Related Items
Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation
Web Exclusives published on May 26, 2020 in FDA Approvals, Prostate Cancer
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals, Prostate Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Prostate Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
August 2018 Vol 11, Special Issue published on August 20, 2018 in Prostate Cancer
Abiraterone a Game-Changer in the Frontline Treatment of Metastatic Prostate Cancer
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights published on August 24, 2017 in Prostate Cancer
Last modified: July 28, 2015
Copyright © Engage Healthcare Communications, LLC. All rights reserved.